|
1
|
Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciccia A and Elledge SJ: The DNA damage
response: Making it safe to play with knives. Mol Cell. 40:179–204.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sørensen CS, Syljuåsen RG, Falck J,
Schroeder T, Rönnstrand L, Khanna KK, Zhou BB, Bartek J and Lukas
J: Chk1 regulates the S phase checkpoint by coupling the
physiological turnover and ionizing radiation-induced accelerated
proteolysis of Cdc25A. Cancer Cell. 3:247–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falck J, Mailand N, Syljuåsen RG, Bartek J
and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against
radio-resistant DNA synthesis. Nature. 410:842–847. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patil M, Pabla N and Dong Z: Checkpoint
kinase 1 in DNA damage response and cell cycle regulation. Cell Mol
Life Sci. 70:4009–4021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tapia-Alveal C, Calonge TM and O'Connell
MJ: Regulation of chk1. Cell Div. 4:82009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y and Hunter T: Roles of Chk1 in
cell biology and cancer therapy. Int J Cancer. 134:1013–1023. 2014.
View Article : Google Scholar
|
|
9
|
Zhang YW, Otterness DM, Chiang GG, Xie W,
Liu YC, Mercurio F and Abraham RT: Genotoxic stress targets human
Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell.
19:607–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leung-Pineda V, Huh J and Piwnica-Worms H:
DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling
cells and in cells experiencing replication stress. Cancer Res.
69:2630–2637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YW, Brognard J, Coughlin C, You Z,
Dolled-Filhart M, Aslanian A, Manning G, Abraham RT and Hunter T:
The F box protein Fbx6 regulates Chk1 stability and cellular
sensitivity to replication stress. Mol Cell. 35:442–453. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB
and Grant S: CHK1 inhibitors in combination chemotherapy: Thinking
beyond the cell cycle. Mol Interv. 11:133–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Merry C, Fu K, Wang J, Yeh IJ and Zhang Y:
Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle.
9:279–283. 2010. View Article : Google Scholar
|
|
14
|
Suganuma M, Kawabe T, Hori H, Funabiki T
and Okamoto T: Sensitization of cancer cells to DNA damage-induced
cell death by specific cell cycle G2 checkpoint abrogation. Cancer
Res. 59:5887–5891. 1999.PubMed/NCBI
|
|
15
|
Kawabe T: G2 checkpoint abrogators as
anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
|
|
16
|
Zhao H, Watkins JL and Piwnica-Worms H:
Disruption of the checkpoint kinase 1/cell division cycle 25A
pathway abrogates ionizing radiation-induced S and G2 checkpoints.
Proc Natl Acad Sci USA. 99:14795–14800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim KS, Heo JI, Choi KJ and Bae S:
Enhancement of cellular radiation sensitivity through degradation
of Chk1 by the XIAP-XAF1 complex. Cancer Biol Ther. 15:1622–1634.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saladin A, Rey J, Thévenet P, Zacharias M,
Moroy G and Tufféry P: PEP-SiteFinder: a tool for the blind
identification of peptide binding sites on protein surfaces.
Nucleic Acids Res. 42:W221–W226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen P, Luo C, Deng Y, Ryan K, Register J,
Margosiak S, Tempczyk-Russell A, Nguyen B, Myers P, Lundgren K, et
al: The 1.7 A crystal structure of human cell cycle checkpoint
kinase Chk1: Implications for Chk1 regulation. Cell. 100:681–692.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao B, Bower MJ, McDevitt PJ, Zhao H,
Davis ST, Johanson KO, Green SM, Concha NO and Zhou BB: Structural
basis for Chk1 inhibition by UCN-01. J Biol Chem. 277:46609–46615.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fuchs SM and Raines RT: Pathway for
polyarginine entry into mammalian cells. Biochemistry.
43:2438–2444. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Han X, Feng X, Wang Z and Zhang Y:
Coupling cellular localization and function of checkpoint kinase 1
(Chk1) in checkpoints and cell viability. J Biol Chem.
287:25501–25509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dunleavy EM, Roche D, Tagami H, Lacoste N,
Ray-Gallet D, Nakamura Y, Daigo Y, Nakatani Y and
Almouzni-Pettinotti G: HJURP is a cell-cycle-dependent maintenance
and deposition factor of CENP-A at centromeres. Cell. 137:485–497.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sidi S, Sanda T, Kennedy RD, Hagen AT,
Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF,
et al: Chk1 suppresses a caspase-2 apoptotic response to DNA damage
that bypasses p53, Bcl-2, and caspase-3. Cell. 133:864–877. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Parsels LA, Qian Y, Tanska DM, Gross M,
Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L,
Simeone DM, et al: Assessment of chk1 phosphorylation as a
pharmaco-dynamic biomarker of chk1 inhibition. Clin Cancer Res.
17:3706–3715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katsuragi Y and Sagata N: Regulation of
Chk1 kinase by auto-inhibition and ATR-mediated phosphorylation.
Mol Biol Cell. 15:1680–1689. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scorah J, Dong MQ, Yates JR III, Scott M,
Gillespie D and McGowan CH: A conserved proliferating cell nuclear
antigen-interacting protein sequence in Chk1 is required for
checkpoint function. J Biol Chem. 283:17250–17259. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smits VA, Reaper PM and Jackson SP: Rapid
PIKK-dependent release of Chk1 from chromatin promotes the
DNA-damage checkpoint response. Curr Biol. 16:150–159. 2006.
View Article : Google Scholar
|
|
29
|
Wang J, Han X and Zhang Y: Autoregulatory
mechanisms of phosphorylation of checkpoint kinase 1. Cancer Res.
72:3786–3794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimada M, Niida H, Zineldeen DH, Tagami
H, Tanaka M, Saito H and Nakanishi M: Chk1 is a histone H3
threonine 11 kinase that regulates DNA damage-induced
transcriptional repression. Cell. 132:221–232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perego P, Gatti L, Righetti SC, Beretta
GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R,
et al: Development of resistance to a trinuclear platinum complex
in ovarian carcinoma cells. Int J Cancer. 105:617–624. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bartucci M, Svensson S, Romania P, Dattilo
R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E,
et al: Therapeutic targeting of Chk1 in NSCLC stem cells during
chemotherapy. Cell Death Differ. 19:768–778. 2012. View Article : Google Scholar :
|
|
34
|
Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X
and Shi H: Chk1 knockdown confers radiosensitization in prostate
cancer stem cells. Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
|
|
35
|
Koniaras K, Cuddihy AR, Christopoulos H,
Hogg A and O'Connell MJ: Inhibition of Chk1-dependent G2 DNA damage
checkpoint radiosensitizes p53 mutant human cells. Oncogene.
20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma CX, Cai S, Li S, Ryan CE, Guo Z,
Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, et al: Targeting
Chk1 in p53-deficient triple-negative breast cancer is
therapeutically beneficial in human-in-mouse tumor models. J Clin
Invest. 122:1541–1552. 2012. View Article : Google Scholar : PubMed/NCBI
|
